This content is only available within our institutional offering.
30 Mar 2017
Leveraging IP without diluting shareholders
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Leveraging IP without diluting shareholders
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
30 Mar 2017 -
Author:
Sanjay Jha -
Pages:
4